Inavolisib is a small molecule inhibitor of phosphatidylinositol 3-kinase and is used in combination with other antineoplastic agents to treat selected adults with locally advanced or metastatic breast cancer. Inavolisib is associated with transient elevations in serum aminotransferase levels during therapy but has not been linked to episodes of clinically apparent liver injury with jaundice. The directory classifies it as a commercial API with a biotechnology source/manufacturing origin. Other names for this substance include Itovebi and GDC-0077. Its PubChem CID is 124173720.
Inavolisib
| CAS No | 2060571-02-8 |
|---|---|
| Molecular Formula | C18H19F2N5O4 |
| Molecular Weight | 407.4 g/mol |
| Synonyms | (2S)-2-[[2-[(4S)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]amino]propanamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Inavolisib is a small molecule inhibitor of phosphatidylinositol 3-kinase and is used in combination with other antineoplastic agents to treat selected adults with locally advanced or metastatic breast cancer.
The listed CAS number is 2060571-02-8.
The listed molecular formula is C18H19F2N5O4.
The listed molecular weight is 407.4 g/mol.
(2S)-2-[[2-[(4S)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]amino]propanamide.
The source lists Itovebi and GDC-0077.